Milestone Pharmaceuticals reported Q1 2026 results, marking the first commercial quarter for CARDAMYST with $0.2 million in revenue and ~600 prescriptions. The company secured Express Scripts National Formulary listing, covering 25% of commercially insured patients. Operating cash burn was $23.7 million, offset by $75 million from a royalty agreement. Net loss narrowed to $26.1 million. Additionally, Milestone initiated the Phase III ReVeRa-301 trial for AFib-RVR.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.